Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rxo (RXO) Cost of Revenue (2021 - 2025)

Rxo (RXO) has disclosed Cost of Revenue for 5 consecutive years, with $1.2 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue fell 11.35% year-over-year to $1.2 billion, compared with a TTM value of $4.6 billion through Dec 2025, up 29.34%, and an annual FY2025 reading of $4.6 billion, up 29.34% over the prior year.
  • Cost of Revenue was $1.2 billion for Q4 2025 at Rxo, up from $1.1 billion in the prior quarter.
  • Across five years, Cost of Revenue topped out at $1.4 billion in Q4 2024 and bottomed at $699.0 million in Q1 2024.
  • Average Cost of Revenue over 5 years is $930.5 million, with a median of $857.0 million recorded in 2022.
  • The sharpest move saw Cost of Revenue decreased 25.66% in 2023, then surged 82.64% in 2024.
  • Year by year, Cost of Revenue stood at $1.1 billion in 2021, then decreased by 19.89% to $842.0 million in 2022, then decreased by 11.76% to $743.0 million in 2023, then surged by 82.64% to $1.4 billion in 2024, then dropped by 11.35% to $1.2 billion in 2025.
  • Business Quant data shows Cost of Revenue for RXO at $1.2 billion in Q4 2025, $1.1 billion in Q3 2025, and $1.1 billion in Q2 2025.